AstraZeneca’s newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says

Now that Alexion’s Soliris is in AstraZeneca’s hands, the drugmaker is counting on the C5 inhibitor to help push it toward billions in sales in just a few years. But a prominent drug pricing watchdog is raising a red flag over its costs for patients with a rare neuromuscular disorder.  The Institute for Clinical and… Read More »

Israeli Data Suggests Possible Waning in Effectiveness of Pfizer Vaccine

The Coronavirus Outbreak Covid-19 Updates Coronavirus Map and Cases Delta Variant Pandemic Relief Programs Ending What is HIPAA? Advertisement Continue reading the main story Supported by Continue reading the main story Israeli Data Suggests Possible Waning in Effectiveness of Pfizer Vaccine The new numbers still show overwhelmingly strong protection against severe disease but diminished effectiveness against… Read More »

Friday Faves

Hi friend! Happy Friday! I hope you’ve had a wonderful week so far. What’s going on this weekend? We’re looking forward to *hopefully* having our first family pool party. The pool is full of water (ahhhhh!) and just need to make sure the balance and everything is good to go. I’ll definitely do a full… Read More »

‘Missing self’ contributes to organ rejection after transplantation

Immune cells called natural killer cells contribute to organ rejection after transplantation because they miss “self” proteins on donor cells, according to a study appearing in an upcoming issue of JASN. A better understanding of this process may help clinicians prevent and treat organ rejection. Transplanted organs are recognized by the immune system of the… Read More »